Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
0.9801
Nov 13 • 3:58 PM ET Dollar change0.0000 Percentage change(0.00%)
Nov 15, 6:45 PMCocrystal Pharma reports fiscal Q3 2026 non-GAAP EPS of $-0.20, misses estimates, while revenue of $105,000 beats estimates
Index
-
Market Cap
18.88M
Enterprise Value
15.19M
Income
-11.33M
Sales
0.43M
Book/sh
0.14
Cash/sh
0.26
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
10
IPO
Apr 01, 2008
P/E
-
Forward P/E
-
PEG
-
P/S
43.91
P/B
7.06
P/C
3.81
P/FCF
-
EV/EBITDA
-
EV/Sales
35.33
Quick Ratio
1.24
Current Ratio
1.72
Debt/Eq
0.47
LT Debt/Eq
0.34
Option/Short
No / Yes
EPS (ttm)
-0.77
EPS next Y
-0.47
EPS next Q
-0.15
EPS this Y
7.05%
EPS next Y
34.48%
EPS next 5Y
6.87%
EPS past 3/5Y
45.26% 17.90%
Sales past 3/5Y
- -
EPS Y/Y TTM
38.55%
Sales Y/Y TTM
-
EPS Q/Q
-6.06%
Sales Q/Q
-
Insider Own
33.53%
Insider Trans
1.33%
Inst Own
5.99%
Inst Trans
10.97%
ROA
-131.63%
ROE
-219.12%
ROIC
-317.36%
Gross Margin
100.00%
Oper. Margin
-2645.98%
Profit Margin
-2605.29%
SMA20
-1.59%
SMA50
-9.32%
SMA200
-10.97%
Trades
Shs Outstand
19.27M
Shs Float
12.81M
52W High
2.03 -51.72%
52W Low
0.76 28.96%
Volatility
7.83% 7.14%
ATR (14)
0.07
RSI (14)
43.54
Beta
1.61
Rel Volume
0.00
Avg Volume
44.99K
Volume
0
Perf Week
-5.76%
Perf Month
-4.84%
Perf Quarter
-10.08%
Perf Half Y
-18.33%
Perf YTD
0.11%
Perf Year
-4.84%
Perf 3Y
-47.87%
Perf 5Y
-91.00%
Perf 10Y
-99.45%
Prev Close
0.98
Price
0.98
Change %
0.00%
Consensus
Strong Buy
Avg. Price Target
$7.00
Implied Upside
+614.2%
Analysts1incl. previous ratings
Rating Distribution1 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jul 08, 2020Initiated
HH.C. Wainwright
Buy$5+410.2%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FROST PHILLIP MD ET ALDirectorAug 05 '26Buy0.9810,0009,8161,993,551Aug 06 05:11 PM
FROST PHILLIP MD ET ALDirectorAug 03 '26Buy0.9475,00070,5901,983,551Aug 05 04:10 PM
FROST PHILLIP MD ET ALDirectorFeb 24 '26Buy1.0020,00019,9521,908,551Feb 25 04:10 PM
FROST PHILLIP MD ET ALDirectorFeb 06 '26Buy0.9550,00047,2801,888,551Feb 09 04:10 PM
FROST PHILLIP MD ET ALDirectorDec 31 '25Buy0.9550,00047,2751,838,551Jan 02 04:10 PM
FROST PHILLIP MD ET ALDirectorDec 30 '25Buy0.9720,00019,3101,788,551Dec 31 04:10 PM
FROST PHILLIP MD ET ALDirectorDec 26 '25Buy0.9740,00038,9441,768,551Dec 29 09:24 AM
FROST PHILLIP MD ET ALDirectorDec 24 '25Buy0.9725,00024,2581,728,551Dec 29 09:24 AM
FROST PHILLIP MD ET ALDirectorNov 26 '25Buy0.994,0003,9751,703,551Nov 28 09:00 AM
FROST PHILLIP MD ET ALDirectorNov 25 '25Buy0.9420,00018,8121,699,551Nov 25 08:17 PM
Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), noroviruses and hepatitis C viruses. Cocrystal employs unique structure-based technologies to create first- and best-in-class antiviral drugs. The company was founded in 2008 and is headquartered in Bothell, WA.
Co-FounderProf. Roger D. Kornberg Ph.D.
Chief Scientific OfficerDr. Sam Lee Ph.D.
M.B.A.Mr. James J. Martin CPA
R.Ph.Mr. James R. Sapirstein M.B.A.